FRT vs RNXT · rev $1.28B vs rev $1.5M
FRT (FRT) versus RenovoRx Inc (RNXT) — a side-by-side from cached financials, not a winner call.
FRT (FRT) common stock.
RenovoRx Inc (RNXT) is a biotechnology company listed on US.
Latest reported FRT revenue for 2025-12-31 was $1.28B. Net income was $411.1M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. FRT currently screens at market cap $0.
Latest reported RNXT revenue for 2026-06-30 was $1.5M. Net income was -$6.4M. RNXT currently screens at market cap $47.0M.
FRT currently screens at market cap $0. RNXT currently screens at market cap $47.0M.
Not investment advice. Open the FRT and RNXT stock pages for the full models.
Not investment advice.